Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. VA BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination VA
News/Events
Local VA News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
News
 Local VA News
 Submit News Release
 Calendar
 Submit Event
 CEO Reading
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: National Center for Missing & Exploited Children
Jobs
 
Advertising
 

NEW University of Washington Basic Bioscience Certificate starts Jan 2009


Medchem Source

Local News

Submit News Release


Search Articles: 

  • Pfizer withdraws application to switch Viagra to non-prescription status in Europe  Pfizer announced that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from 'prescription only' to 'non-prescription' in the European Union (EU).
    Pfizer Inc. November 20, 2008  
  • AstraZeneca granted temporary restraining order in PULMICORT RESPULES patent litigation  On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation suspension product, a generic version of AstraZeneca's PULMICORT RESPULES treatment.
    AstraZeneca November 20, 2008  
  • AstraZeneca to realign supply chain to improve productivity and move closer to customers  AstraZeneca has announced proposed changes to its global manufacturing and supply chain operations as part of its ongoing programme to improve efficiency across the business.
    AstraZeneca November 20, 2008  
  • Amgen, Takeda and Millennium provide update on Phase 3 trial of motesanib  Amgen and Millennium announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended.
    Amgen November 19, 2008  
  • AstraZeneca enters agreement for authorized generic Pulmicort Respules  AstraZeneca announced that it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of budesonide inhalation suspension in the United States in response to the launch 'at risk' of a generic version of this product by Teva.
    AstraZeneca November 19, 2008  
  • PharmAthene signs agreement with Medison Pharma  PharmAthene, a biodefense company developing medical countermeasures against biological and chemical threats, announced that it has signed an agreement with Medison Pharma, to commercialize its biodefense products in Israel.
    PharmAthene November 19, 2008  
  • More seek share of smaller funds from Maryland Stem Cell Research Commission  The Maryland Stem Cell Research Commission has received 187 letters of intent from researchers vying to win $18 million in state funding. Officials said the level of interest outpaces the 127 requests the commission received last year.
    Baltimore Business Journal November 19, 2008  Sue Schultz
  • FDA opens 1st office in China  U.S. officials are launching a new strategy to improve the safety of the vast range of foods and other products imported from China and other countries to the United States. The Food and Drug Administration is opening its first office outside the United States in Beijing.
    Austin American-Statesman (Texas) November 19, 2008  Craig Simons
  • MiddleBrook Pharmaceuticals hires key commercial team members  MiddleBrook Pharmaceuticals announced it has hired key commercial team members. Frank L. Koos has joined MiddleBrook Pharmaceuticals as senior vice president, sales & business development.
    MiddleBrook Pharmaceuticals, Inc. November 19, 2008  
  • GenVec announces interim survival data in pivotal trial of TNFerade(TM)  GenVec announced top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) in patients with locally advanced pancreatic cancer.
    GenVec, Inc. November 19, 2008  

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2008 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

VirginiaLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of Virginia.